The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2016 | The future of drug development: broader signatures in precision medicine, beyond genomics
Yu Shyr, PhD of Vanderbilt University School of Medicine, Nashville, TN discusses drug development in lung cancer and a need for a broader approach, using genomics, proteomics, and lipidomics to create a signature or network in personalized precision medicine. Currently, most drug development focuses on targeted therapy for single gene mutations with low prevalence rates. There is an obvious lack of focus on those patients without these mutations. Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.
